# US 2026/0096984 A1 · Implantable Device for Administering a Therapeutic Agent > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2026/0096984 A1 - Document ID: US20260096984A1 - Status: Published application - Kind: A1 - Application number: 19/348,846 - Filed: 2025-10-03 - Published: 2026-04-09 - Earliest claimed: 2024-10-07 - Assignees: Celanese EVA Performance Polymers LLC - Applicants: Celanese EVA Performance Polymers LLC - Inventors: Harsh Patel; Jeffrey Haley - Web page: https://patentgrep.com/patent/US20260096984A1 ## CPC - A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)} - A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465) - A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers - A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence) - C07K 16/32: against translation products of oncogenes - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) ## Abstract An implantable device for the delivery of a therapeutic agent is provided. The implantable device includes a core having a core polymer matrix within which is dispersed one or more therapeutic agents. The core polymer matrix includes a hydrophobic polymer comprising a first poly ortho ester (POE) polymer. The first POE polymer has a Tg of between about −20° C. and 40° C. as determined in accordance with ASTM E1640-18. Methods for forming the implantable device are also provided. ## Claims ### Claim 1 An implantable device for delivery of a therapeutic agent, comprising: a core comprising a core polymer matrix within which is dispersed one or more therapeutic agents, wherein the core polymer matrix comprises a hydrophobic polymer comprising a first poly ortho ester (POE) polymer, wherein the first POE polymer has a Tg of between about −20° C. and 40° C. as determined in accordance with ASTM E1640-18. ### Claim 2 (depends on 1) The implantable device of claim 1, wherein the one or more therapeutic agents constitute from about 40 wt. % to about 70 wt. % of the core. ### Claim 3 (depends on 1) The implantable device of claim 1, wherein the weight ratio of the one or more therapeutic agents to the core polymer matrix is from about 0.7 to about 2. ### Claim 4 (depends on 1) The implantable device of claim 1, wherein the core polymer matrix constitutes from about 30 wt. % to about 50 wt. % of the device. ### Claim 5 (depends on 1) The implantable device of claim 1, wherein the POE polymer has an acetal monomer content of from about 20 mol. % to about 80 mol. %. ### Claim 6 (depends on 1) The implantable device of claim 1, wherein the POE polymer has a polyol monomer content of from about 20 mol. % to about 80 mol. %. ### Claim 7 (depends on 6) The implantable device of claim 6, wherein the polyol monomer content comprises from about 1 mol. % to about 60 mol. % of one or more modified polyols. ### Claim 8 (depends on 1) The implantable device of claim 1, wherein the POE polymer has a weight-average molecular weight of from about 1 kDa to about 100 kDa. ### Claim 9 (depends on 1) The implantable device of claim 1, wherein the first POE polymer has a Tg of between about 0° C. and 40° C. as determined in accordance with ASTM E1640-18. ### Claim 10 (depends on 1) The implantable device of claim 1, wherein the one or more therapeutic agents comprise one or more antipsychotics. ### Claim 11 (depends on 1) The implantable device of claim 1, wherein the one or more therapeutic agents comprise a glucagon-like peptide-1 (GLP-1) receptor agonist. ### Claim 12 (depends on 1) The implantable device of claim 1, wherein the device has a thickness of from about 0.1 to about 10 millimeters and/or a length of about 1 to about 250 millimeters. ### Claim 13 (depends on 1) The implantable device of claim 1, wherein the core is formed from a hot melt extrusion process. ### Claim 14 (depends on 1) A method for prohibiting and/or treating a condition, disease, and/or cosmetic state of a patient in need thereof, the method comprising implanting the device of claim 1 in the patient. ### Claim 15 A method of manufacturing an implantable device, comprising: melt-blending a core polymer matrix containing a first POE polymer and one or more therapeutic agents in an extruder barrel at a first temperature, the first temperature ranging from about 40° C. to about 70° C., the first POE polymer having a Tg of from about −20° C. to about 40° C. as determined in accordance with ASTM E1640-18; mixing the core polymer matrix and therapeutic agent in the extruder barrel at a second temperature to form a mixture of core polymer matrix and one or more therapeutic agents, the second temperature ranging from about 40° C. to about 70° C.; extruding the mixture of core polymer matrix and one or more therapeutic agents from the extruder barrel forming a core of the implantable device; cooling the core; and cutting the core to form the implantable device. ### Claim 16 (depends on 15) The method of claim 15, wherein the one or more therapeutic agents constitute from about 40 wt. % to about 70 wt. % of the core. ### Claim 17 (depends on 15) The method of claim 15, wherein the weight ratio of the one or more therapeutic agents to the core polymer matrix is from about 0.7 to about 2. ### Claim 18 (depends on 15) The method of claim 15, wherein the POE polymer has an acetal monomer content of about 20 mol. % to about 80 mol. %. ### Claim 19 (depends on 15) The method of claim 15, wherein the POE polymer has a polyol monomer content that comprises from about 1 mol. % to about 60 mol. % of one or more modified polyols. ### Claim 20 (depends on 15) The method of claim 15, wherein the one or more therapeutic agents comprise one or more GLP-1 receptor agonists.